Combined treatment with serine protease inhibitor aprotinin and matrix metalloproteinase inhibitor Batimastat (BB-94) does not prevent invasion of human esophageal and ovarian carcinoma cells in vivo.
Year: 1999
Type: article
Source: PubMed
Authors: P Della Porta, R Soeltl, H W Krell, K Collins, M O'Donoghue, M Schmitt, A Krüger
Institution: Technical University of Munich
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W2470712598
